An Investigational Study to Evaluate Experimental Medication BMS-986165 in Japanese Participants With Moderate-to-Severe Psoriasis

Study Purpose

The purpose of this study is to investigate BMS-986165 given to Japanese participants with moderate-to-severe psoriasis.

Recruitment Criteria

Accepts Healthy Volunteers

Healthy volunteers are participants who do not have a disease or condition, or related conditions or symptoms

No
Study Type

An interventional clinical study is where participants are assigned to receive one or more interventions (or no intervention) so that researchers can evaluate the effects of the interventions on biomedical or health-related outcomes.


An observational clinical study is where participants identified as belonging to study groups are assessed for biomedical or health outcomes.


Searching Both is inclusive of interventional and observational studies.

Interventional
Eligible Ages 20 Years and Over
Gender All
More Inclusion & Exclusion Criteria

For more information regarding Bristol-Myers Squibb Clinical Trial participation, please visit www.BMSStudyConnect.com

Inclusion Criteria:

a. For participants with plaque psoriasis: i. Stable plaque psoriasis for at least 6 months ii. Moderate to severe disease iii. Candidate for phototherapy or systemic therapy b. Additional protocol-specified inclusion criteria apply for subjects with psoriatic arthritis, erythrodermic psoriasis, or generalized pustular psoriasis

Exclusion Criteria:

1. Guttate, inverse, or drug-induced psoriasis at Screening or Baseline 2. History of recent infection 3. Prior exposure to BMS-986165 Other protocol defined inclusion/exclusion criteria could apply

Trial Details

Trial ID:

This trial id was obtained from ClinicalTrials.gov, a service of the U.S. National Institutes of Health, providing information on publicly and privately supported clinical studies of human participants with locations in all 50 States and in 196 countries.

NCT03924427
Phase

Phase 1: Studies that emphasize safety and how the drug is metabolized and excreted in humans.

Phase 2: Studies that gather preliminary data on effectiveness (whether the drug works in people who have a certain disease or condition) and additional safety data.

Phase 3: Studies that gather more information about safety and effectiveness by studying different populations and different dosages and by using the drug in combination with other drugs.

Phase 4: Studies occurring after FDA has approved a drug for marketing, efficacy, or optimal use.

Phase 3
Lead Sponsor

The sponsor is the organization or person who oversees the clinical study and is responsible for analyzing the study data.

Bristol-Myers Squibb
Principal Investigator

The person who is responsible for the scientific and technical direction of the entire clinical study.

Bristol-Myers Squibb
Principal Investigator Affiliation Bristol-Myers Squibb
Agency Class

Category of organization(s) involved as sponsor (and collaborator) supporting the trial.

Industry
Overall Status Recruiting
Countries Japan
Conditions

The disease, disorder, syndrome, illness, or injury that is being studied.

Psoriasis
Study Website: View Trial Website
Arms & Interventions

Arms

Experimental: BMS-986165

Given daily

Interventions

Drug: - BMS-986165

Oral tablet administration

Contact a Trial Team

If you are interested in learning more about this trial, find the trial site nearest to your location and contact the site coordinator via email or phone. We also strongly recommend that you consult with your healthcare provider about the trials that may interest you and refer to our terms of service below.

International Sites

Nagoya City University Hospital, Nagoya, Aichi, Japan

Status

Recruiting

Address

Nagoya City University Hospital

Nagoya, Aichi, 467-8602

Site Contact

Akimichi Morita, Site 0014

Clinical.Trials@bms.com

please email:

Ehime University Hospital, Toon-Shi, Ehime, Japan

Status

Recruiting

Address

Ehime University Hospital

Toon-Shi, Ehime, 791-0295

Site Contact

Jun Muto, Site 0013

Clinical.Trials@bms.com

please email:

Fukuoka University Hospital, Fukuoka-shi, Fukuoka, Japan

Status

Recruiting

Address

Fukuoka University Hospital

Fukuoka-shi, Fukuoka, 814-0180

Site Contact

Shinichi Imafuku, Site 0010

Clinical.Trials@bms.com

please email:

Local Institution, Kitakyushu, Fukuoka, Japan

Status

Recruiting

Address

Local Institution

Kitakyushu, Fukuoka, 807-8555

Site Contact

Site 0002

Clinical.Trials@bms.com

please email:

Sapporo Skin Clinic, Sapporo, Hokkaido, Japan

Status

Recruiting

Address

Sapporo Skin Clinic

Sapporo, Hokkaido, 060-0063

Site Contact

Masatoshi Abe, Site 0021

Clinical.Trials@bms.com

please email:

Kobe University Hospital, Kobe, Hyogo, Japan

Status

Recruiting

Address

Kobe University Hospital

Kobe, Hyogo, 6500017

Site Contact

Makoto Kunisada, Site 0011

Clinical.Trials@bms.com

please email:

Local Institution, Morioka, Iwate, Japan

Status

Not yet recruiting

Address

Local Institution

Morioka, Iwate, 0208505

Site Contact

Site 0008

Clinical.Trials@bms.com

please email:

Tokai University Hospital, Isehara City, Kanagawa, Japan

Status

Recruiting

Address

Tokai University Hospital

Isehara City, Kanagawa, 259-1193

Site Contact

Tomotaka Mabuchi, Site 0023

Clinical.Trials@bms.com

please email:

Yokohama City University Hospital, Yokohama-shi, Kanagawa, Japan

Status

Recruiting

Address

Yokohama City University Hospital

Yokohama-shi, Kanagawa, 2360004

Site Contact

Yukie Yamaguchi, Site 0001

Clinical.Trials@bms.com

please email:

Local Institution, Yokohama-shi, Kanagawa, Japan

Status

Recruiting

Address

Local Institution

Yokohama-shi, Kanagawa, 2458575

Site Contact

Site 0024

Clinical.Trials@bms.com

please email:

Local Institution, Nakoku, Kochi, Japan

Status

Recruiting

Address

Local Institution

Nakoku, Kochi, 783-8505

Site Contact

Site 0025

Clinical.Trials@bms.com

please email:

Local Institution, Kyoto-city, Kyoto, Japan

Status

Recruiting

Address

Local Institution

Kyoto-city, Kyoto, 602-8566

Site Contact

Site 0022

Clinical.Trials@bms.com

please email:

Mie University Hospital, Tsu, MIE, Japan

Status

Recruiting

Address

Mie University Hospital

Tsu, MIE, 514-8507

Site Contact

Keiichi Yamanaka, Site 0007

Clinical.Trials@bms.com

please email:

Shinshu University Hospital, Matsumoto, Nagano, Japan

Status

Recruiting

Address

Shinshu University Hospital

Matsumoto, Nagano, 3908621

Site Contact

Eisaku Ogawa, Site 0004

Clinical.Trials@bms.com

please email:

Local Institution, Kurashiki, Okayama, Japan

Status

Recruiting

Address

Local Institution

Kurashiki, Okayama, 7108602

Site Contact

Site 0026

Clinical.Trials@bms.com

please email:

Osaka City University Hospital, Osaka-shi, Osaka, Japan

Status

Recruiting

Address

Osaka City University Hospital

Osaka-shi, Osaka, 5458586

Site Contact

Chiharu Tateishi, Site 0003

Clinical.Trials@bms.com

please email:

Hamamatsu University Hospital, Hamamatsu, Shizuoka, Japan

Status

Recruiting

Address

Hamamatsu University Hospital

Hamamatsu, Shizuoka, 431-1192

Site Contact

Taisuke Ito, Site 0006

Clinical.Trials@bms.com

please email:

Jichi Medical University Hospital, Shimotsuke, Tochigi, Japan

Status

Recruiting

Address

Jichi Medical University Hospital

Shimotsuke, Tochigi, 329-0498

Site Contact

Mayumi Komine, Site 0020

Clinical.Trials@bms.com

please email:

Nihon University Itabashi Hospital, Itabashi-ku, Tokyo, Japan

Status

Recruiting

Address

Nihon University Itabashi Hospital

Itabashi-ku, Tokyo, 173-8610

Site Contact

Tadashi Terui, Site 0027

Clinical.Trials@bms.com

please email:

Teikyo University Hospital, Itabashi, Tokyo, Japan

Status

Recruiting

Address

Teikyo University Hospital

Itabashi, Tokyo, 173-8605

Site Contact

Yayoi Tada, Site 0018

Clinical.Trials@bms.com

please email:

Local Institution, Minato-ku, Tokyo, Japan

Status

Recruiting

Address

Local Institution

Minato-ku, Tokyo, 105-8471

Site Contact

Site 0019

Clinical.Trials@bms.com

please email:

Local Institution, Shinagawa, Tokyo, Japan

Status

Recruiting

Address

Local Institution

Shinagawa, Tokyo, 141-8625

Site Contact

Site 0017

Clinical.Trials@bms.com

please email:

Local Institution, Shinjuku-ku, Tokyo, Japan

Status

Recruiting

Address

Local Institution

Shinjuku-ku, Tokyo, 1600023

Site Contact

Site 0016

Clinical.Trials@bms.com

please email:

Shinjuku, Tokyo, Japan

Status

Recruiting

Address

Japan Community Health Care Organization Tokyo Yamate Medical Center

Shinjuku, Tokyo, 169-0073

Site Contact

Hideshi Torii, Site 0015

Clinical.Trials@bms.com

please email:

Local Institution, Kumamoto, Japan

Status

Recruiting

Address

Local Institution

Kumamoto, , 860-8556

Site Contact

Site 0009

Clinical.Trials@bms.com

please email:

Local Institution, Kyoto, Japan

Status

Recruiting

Address

Local Institution

Kyoto, , 606-8507

Site Contact

Site 0005

Clinical.Trials@bms.com

please email:

Nippon Life Hospital, Osaka, Japan

Status

Recruiting

Address

Nippon Life Hospital

Osaka, , 550-0006

Site Contact

Mari Higashiyama, Site 0012

Clinical.Trials@bms.com

please email:

The content provided on clinical trials is for informational purposes only and is not a substitute for medical consultation with your healthcare provider. We do not recommend or endorse any specific study and you are advised to discuss the information shown with your healthcare provider. While we believe the information presented on this website to be accurate at the time of writing, we do not guarantee that its contents are correct, complete, or applicable to any particular individual situation. We strongly encourage individuals to seek out appropriate medical advice and treatment from their physicians. We cannot guarantee the availability of any clinical trial listed and will not be responsible if you are considered ineligible to participate in a given clinical trial. We are also not liable for any injury arising as a result of participation.